Carregant...
Deubiquitylating enzymes and drug discovery: emerging opportunities
More than a decade after a Nobel Prize was awarded for the discovery of the ubiquitin–proteasome system and clinical approval of proteasome and ubiquitin E3 ligase inhibitors, first-generation deubiquitylating enzyme (DUB) inhibitors are now approaching clinical trials. However, although our knowled...
Guardat en:
| Publicat a: | Nat Rev Drug Discov |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7097658/ https://ncbi.nlm.nih.gov/pubmed/28959952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrd.2017.152 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|